New Report: Advances in the Stem Cell Industry: The Future Impact of Innovation

LONDON, December 1 - Global stem cell market sales reached $410 million in 2008, and will grow
to $2.68 billion by 2012 according to a new report on
www.companiesandmarkets.com.

Advances in the Stem Cell Industry: The Future Impact Of Innovation, And
An Evaluation Of The Commercial Landscape

www.companiesandmarkets.com/r.ashx?id=3CP03OFNH168616

An important milestone in the development of stem cell technology
occurred in 2007, when researchers induced human cells into a stem cell state
using defined genetic factors. These cells are now known as induced
pluripotent stem (IPS) cells; they offer an alternative to using embryonic
stem cells. This report takes the implications of IPS cells and other
developments into account. Some essential technologies are already in place
and stem-cell based therapies have already begun to appear in the
marketplace. This has enabled the author to build market estimates based on
emerging commercial realities. The stem cell market is already divided into
three segments-cell-based treatments, umbilical cord blood banking, and the
use of stem cells to evaluate the efficacy and safety of new drugs developed
by other methods. Global sales reached $410 million in 2008, and will grow to
$2.68 billion by 2012. This growth will reach a projected $5.1 billion in
2014, providing a realistic, and even cautious forecast of the commercial
potential of these segments.

The report also describes the potential for stem cell science as applied
to drug discovery and toxicity testing. To give a full industry perspective,
the report offers profiles of a large number (approximately 50) of companies
operating in this field, including all sizes and types of organisation from
small start-ups based on a single technology to large concerns with
established product portfolios. This report also describes the background of
stem cell science and the current status of knowledge in this sphere. The
approach does not shirk essential technical detail but it is written in an
easily readable style and the depth of information provided is carefully
assessed.

Key features of this report

Provides current status of the stem cell market, essential in a
fast-moving field where up-to-date knowledge is paramount.

Another key quality for a report such as this is that it should be
realistic. Whether one describes the glass as half-full or half-empty matters
less than describing it as a half glassful. Market forecasts are refined to
indicate the potential offered by this exciting new area of technology
without ignoring the practical difficulties.

The scope for medical applications of stem cell science is broad and the
report attempts to give as full a picture as possible, including applications
that are as yet in development as well as those which are more advanced.

The report also describes the potential for stem cell science as applied
to drug discovery and toxicity testing

To give a full industry perspective, the report offers profiles of a
large number (approximately 50) of companies operating in this field,
including all sizes and types of organisation from small start-ups based on a
single technology to large concerns with established product portfolios.

The report describes the background of stem cell science and the current
status of knowledge in this sphere. The approach does not shirk essential
technical detail but it is written in an easily readable style and the depth
of information provided is carefully assessed.

Key findings from this report

The main focus of applied stem cell research has been to explore the
possibilities of using SCs in regenerative medicine, to replace normal cells
and tissues destroyed by disease or trauma.

Primary therapeutic targets are nervous system disorders such as
Parkinson's disease and amyotrophic lateral sclerosis; cardiovascular disease
including heart failure, myocardial infarction and severe peripheral arterial
disease.

Stem cell science also offers the prospect of contributing to new drug
discovery, for example by providing in vitro targets that can identify
promising new candidates before any in vivo work has been undertaken.

Cell-based therapies may be divided into those using autologous cells and
those using allogeneic cells. Each market has its own characteristics.

The world market for cell-based therapies is now estimated at $600
million, but there is great growth potential, given the high prevalence of
eligible patients, once appropriate products reach the marketplace.

The US accounts for about 90% of the world market but other national
markets will make inroads over the coming years, and grow faster than the US
market.

Attrition among companies and products in the regenerative medicine
market indicate that this is a demanding market environment requiring care in
the choice of appropriate marketing model.

Key questions answered by this report

What are the main hitherto untreatable conditions for which stem cell
therapy may provide new hope of cure?

Are embryo or adult stem cells the best prospect for future
commercialization?

What is the present size of the global stem cell market, and how is it
expected to grow?

Which are the leading national markets for stem cell products?

What is the nature of the ethical objection to stem cell manipulation?

What important factors need to be taken into account when formulating a
business plan for stem cell commercialization?

Names the leading companies with stem cell products in advanced
development.

Apart from the treatment of disease, what other roles are envisaged for
stem cell products?

What are induced pluripotent stem cells, and why are they important?

Advances in the Stem Cell Industry: The Future Impact Of Innovation, And
An Evaluation Of The Commercial Landscape

www.companiesandmarkets.com/r.ashx?id=3CP03OFNH168616

Mike King, info@companiesandmarkets.com, +44-0203-086-8600

Mike King, info at companiesandmarkets.com, +44-0203-086-8600